Alembic Pharmaceuticals Limited · NSE:APLLTD

Alembic Pharmaceuticals — Investor Presentation (December 2019)

15 slides from Alembic Pharmaceuticals's investor presentation, December 2019

  1. Slide 1: Alembic Pharmaceuticals Limited Investor presentation – December 2019

    Alembic Pharmaceuticals Limited Investor presentation – December 2019 BSE & NSE: APLLTD

  2. Slide 2: Milestones

    Milestones 1907 Established by Amin family 2006 FDA approves API facility 2007 Acquired Dabur’s Indian Cardiology, GI and Gynaecology brands 2008 FDA approves Formulation facility 2010 Pharmaceuticals business demerged from Alembic – APL listed 2012 Formed a JV, Rhizen, for NCE research Launched fir

  3. Slide 3: Financial Highlights

    Financial Highlights INR Bn Particulars Q3 FY20 Q3 FY19 Growth YTD FY20 YTD FY19 Growth FY19 Net Sales 12.09 10.18 19% 33.99 30.08 13% 39.35 EBIDTA Pre R&D 4.66 3.51 33% 13.35 10.61 26% 13.38 Margin % 39% 34% 39% 35% 34% R&D 1.46 1.12 30% 4.60 3.79 22% 4.98 R&D % 12% 11% 14% 13% 13% EBIDTA Post R&D

  4. Slide 4: Business snapshot – Q3FY20

    Business snapshot – Q3FY20 Formulations Generics Branded API Total US Ex-US India Revenue Q3FY20 (INR Bn) 5.15 1.49 3.68 1.77 12.09 API Vet 15% 15% 3% Generics Q3FY20 Revenue 43% Acute 55% Contribution 11% Branded 30% 12% Speciality 16% Growth Q3FY20 -14% 61% 15% 1% 19% over Q3FY19 Growth Q3FY20 -4%

  5. Slide 5: Business snapshot – YTD FY20

    Business snapshot – YTD FY20 Formulations Generics Branded API Total US Ex-US India Revenue YTD FY20 (INR Bn) 13.99 3.64 10.83 5.53 33.99 API Vet 16% 16% 3% Generics YTD FY20 Revenue 41% 52% Acute Contribution 11% Branded 32% 11% Speciality 17% Growth YTD FY20 -12% 43% 0% 2% 13% over YTD FY19 • Well

  6. Slide 6: US Generic

    US Generic Revenue – Q3 FY20 INR Bn Revenue – Last 5 Years CAGR - 42% INR Bn 12.28 12.88 5.15 9.19 9.20 3.19 3.16 Q3FY19 Q3FY20 FY15 FY16 FY17 FY18 FY19 Approved ANDAs Milestones & Updates Derma 7 Opthalmic ➢ The Aleor derma facility at Karakhadi was audited by USFDA without 11 any observations Tota

  7. Slide 7: Ex-US Generics

    Ex-US Generics Revenue : Q3 FY20 INR Bn Revenue – Last 5 Years INR Bn CAGR - 17% 1.49 1.29 4.94 Q3FY19 Q3FY20 3.20 ➢ Presence in following markets 2.86 2.66 - Europe, Canada, Australia, Brazil and South Africa 2.34 ➢ The business will focus on new launches across key markets ➢ Plant successfully aud

  8. Slide 8: API

    API Revenue : Q3 FY20 INR Bn Revenue – Last 5 Years INR Bn CAGR - 20% 2.05 1.77 7.71 6.40 6.51 Q3FY19 Q3FY20 5.25 ➢ Sales across geographies as preferred supplier 3.67 ➢ Investing in plants to create additional capacities ➢ FDA Compliant plants ➢ State of the art R&D center and Process development l

  9. Slide 9: R&D: Significant investments in building capabilities

    R&D Significant 8.0 investments in building capabilities INR Bn ANDA – Accelerated filings & approvals 37* Filing 6.0 13.7% 13.1% 12.7% 29 Approval 10.1% R&D Spend 4.0 20 19 18* * 11 Filings & 6.3% 7 Approvals 5.0 R&D % of were 2.0 4.3 4.1 10 sales 8 contributed by 3.2 7 7 5 acquisition of 1.3 Orit,

  10. Slide 10: State of the art facilities and infrastructure

    State of the art facilities and infrastructure Audit/Filing Location Dosage Form status International Generics F1 – Panelav General Oral Solids Oct’18* Oncology Oral Solids Jun’19* F2 – Panelav Oncology Injectables H2FY21# F2 - Panelav F3 - Karkhadi General Injectables F3 – Karkhadi Ophthalmic H2FY2

  11. Slide 11: Branded Business

    Branded Business Revenue – Q3 FY20 INR Bn Revenue – Last 5 Years CAGR - 6% INR Bn 13.8 3.65 3.68 12.5 12.7 1% ↑ 11.8 0.37 0.37 11.0 Vet 1.27 1.37 Acute Speciality 1.99 1.93 Q3FY19 Q3FY20 FY15 FY16 FY17 FY18 FY19 Marketing organization Key achievements ➢ 5000 + Marketing team ➢ 3 Brands in top 300 ➢

  12. Slide 12: Therapy-wise Performance Q3 FY20

    Therapy-wise Performance Q3 FY20 Q3 FY20 Q3 FY19 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy (%) Growth Share % Growth % Growth % Growth Share Growth % Growth % % (ORG) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Cardiology 10 2.08 4 6 13 2.19 23 16 Anti Diabetic 10 1.4

  13. Slide 13: Therapy-wise Performance YTD Dec’19

    Therapy-wise Performance YTD Dec’19 YTD Dec’19 YTD Dec’18 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy (%) Growth Share % Growth % Growth % Growth Share Growth % Growth % % (ORG) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Cardiology 11 2.08 5 3 13 2.19 22 18 Anti Diabet

  14. Slide 14: Financials: Generating consistent returns

    Financials : Generating consistent returns Revenue EBIDTA Capex INR Bn INR Bn INR Bn 10.07 39.35 6.04 6.26 8.75 31.62 31.34 31.31 4.91 6.15 6.42 20.53 3.09 4.03 2.13 FY15 FY16 FY17 FY18 FY19 FY15 FY16 FY17 FY18 FY19 FY15 FY16 FY17 FY18 FY19 CAGR - 18% CAGR - 21% Net Profit EBIDTA margin % ROCE % INR

  15. Slide 15: Thank you

    Thank you Safe Harbour Agreement: Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and resu

Alembic Pharmaceuticals — Investor Presentation (December 2019) on 6ix